112 related articles for article (PubMed ID: 11390120)
1. Dose-ranging studies of a novel intranasal estrogen replacement therapy.
Panay N; Toth K; Pelissier C; Studd J
Maturitas; 2001 Jun; 38 Suppl 1():S15-22. PubMed ID: 11390120
[TBL] [Abstract][Full Text] [Related]
2. Aerodiol versus the transdermal route: perspectives for patient preference.
Lopes P; Rozenberg S; Graaf J; Fernandez-Villoria E; Marianowski L
Maturitas; 2001 Jun; 38 Suppl 1():S31-9. PubMed ID: 11390122
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and acceptability of intranasal 17 beta-oestradiol for menopausal symptoms: randomised dose-response study. Aerodiol Study Group.
Studd J; Pornel B; Marton I; Bringer J; Varin C; Tsouderos Y; Christiansen C
Lancet; 1999 May; 353(9164):1574-8. PubMed ID: 10334256
[TBL] [Abstract][Full Text] [Related]
4. Clinical equivalence of intranasal estradiol and oral estrogens for postmenopausal symptoms.
Ozsoy M; Oral B; Ozsoy D
Int J Gynaecol Obstet; 2002 Nov; 79(2):143-6. PubMed ID: 12427399
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic value and long-term safety of pulsed estrogen therapy.
Dören M; Azzawi FA; Donnez J; Van der Mooren MJ; Villero J; Gompel A
Maturitas; 2001 Jun; 38 Suppl 1():S23-30. PubMed ID: 11390121
[TBL] [Abstract][Full Text] [Related]
6. [Aerodiol: the efficacy and tolerability of intranasal estrogen administration. An overview].
Genazzani AR; Cappagli B; Ciaponi M
Minerva Ginecol; 2003 Jun; 55(3):189-200. PubMed ID: 14581864
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and tolerability of pulsed estrogen therapy: a 12-week double-blind placebo-controlled study in highly symptomatic postmenopausal women.
Rozenbaum H; Chevallier O; Moyal M; Durand G; Perineau M; This P;
Climacteric; 2002 Sep; 5(3):249-58. PubMed ID: 12419083
[TBL] [Abstract][Full Text] [Related]
8. Pulsed estrogen therapy: relieving climacteric symptoms, preventing postmenopausal bone loss.
Palacios S
Climacteric; 2002 Jun; 5 Suppl 2():32-9. PubMed ID: 12482109
[TBL] [Abstract][Full Text] [Related]
9. Clinical equivalence of intranasal and oral 17beta-estradiol for postmenopausal symptoms.
Mattsson LA; Christiansen C; Colau JC; Palacios S; Kenemans P; Bergeron C; Chevallier O; Von Holst T; Gangar K
Am J Obstet Gynecol; 2000 Mar; 182(3):545-52. PubMed ID: 10739506
[TBL] [Abstract][Full Text] [Related]
10. Clinical evaluation, dose-finding and acceptability of AERODIOL, the pulsed estrogen therapy for treatment of climacteric symptoms.
Pelissier C; de Kervasdoue A; Chuong VT; Maugis EL; de Mouillac F; Breil MH; Moniot G; Zeitoun-Lepvrier G; Robin M; Rime B
Maturitas; 2001 Jan; 37(3):181-9. PubMed ID: 11173180
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and tolerability of a new 7-day transdermal estradiol patch versus placebo in hysterectomized women with postmenopausal complaints.
von Holst T; Salbach B
Maturitas; 2000 Feb; 34(2):143-53. PubMed ID: 10714909
[TBL] [Abstract][Full Text] [Related]
12. Effects of low-dose norethindrone acetate plus ethinyl estradiol (0.5 mg/2.5 microg) in women with postmenopausal symptoms: updated analysis of three randomized, controlled trials.
Rowan JP; Simon JA; Speroff L; Ellman H
Clin Ther; 2006 Jun; 28(6):921-32. PubMed ID: 16860174
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of a new 7-day transdermal sequential estradiol/levonorgestrel patch in women.
von Holst T; Salbach B
Maturitas; 2002 Mar; 41(3):231-42. PubMed ID: 11886769
[TBL] [Abstract][Full Text] [Related]
14. [Evaluation the efficacy and safety of estradiol and drospirenone tablets in the treatment of menopausal symptoms among postmenopausal Chinese healthy women:a randomized, multi-center, double-blind, placebo-controlled clinical study].
Zhou YZ; Sun LZ; Lin JF; Yang X; Zhang LJ; Qiao J; Wang ZH; Xu YX; Xiong ZA; Lin SQ
Zhonghua Fu Chan Ke Za Zhi; 2011 May; 46(5):345-9. PubMed ID: 21733370
[TBL] [Abstract][Full Text] [Related]
15. Effects on serum lipid and leptin levels of three different doses of norethisterone continuously combined with a fixed dose of 17beta-estradiol for nasal administration in postmenopausal women: a controlled, double-blind study.
Castelo-Branco C; Palacios S; Vázquez F; Villero J; Ferrer J; Ascaso C; Balasch J
Fertil Steril; 2007 Aug; 88(2):383-9. PubMed ID: 17561009
[TBL] [Abstract][Full Text] [Related]
16. A dose-ranging trial of a matrix transdermal 17beta-estradiol for the prevention of bone loss in early postmenopausal women. International Study Group.
Delmas PD; Pornel B; Felsenberg D; Garnero P; Hardy P; Pilate C; Dain MP
Bone; 1999 May; 24(5):517-23. PubMed ID: 10321913
[TBL] [Abstract][Full Text] [Related]
17. Dose-response efficacy of a new estradiol transdermal matrix patch for 7-day application: a randomized, double-blind, placebo-controlled study. Italian Menopause Research Group.
Rovati LC; Setnikar I; Genazzani AR
Gynecol Endocrinol; 2000 Aug; 14(4):282-91. PubMed ID: 11075300
[TBL] [Abstract][Full Text] [Related]
18. Effects of the route of estrogen administration on insulinlike growth factor-I, IGF binding protein-3, and insulin resistance in healthy postmenopausal women: results from a randomized, controlled study.
Davis SR; Stuckey BG; Norman RJ; Papalia MA; Drillich A; Bell RJ
Menopause; 2008; 15(6):1065-9. PubMed ID: 18806686
[TBL] [Abstract][Full Text] [Related]
19. Vasomotor hot flashes and heart rate variability: a placebo-controlled trial of postmenopausal hormone therapy.
Lantto H; Haapalahti P; Tuomikoski P; Viitasalo M; Väänänen H; Sovijärvi AR; Ylikorkala O; Mikkola TS
Menopause; 2012 Jan; 19(1):82-8. PubMed ID: 21934534
[TBL] [Abstract][Full Text] [Related]
20. A randomized, double-blind, placebo-controlled study of the lowest effective dose of drospirenone with 17β-estradiol for moderate to severe vasomotor symptoms in postmenopausal women.
Archer DF; Schmelter T; Schaefers M; Gerlinger C; Gude K
Menopause; 2014 Mar; 21(3):227-35. PubMed ID: 23963307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
